Vera Therapeutics, Inc. (VERA) News
Follow Vera Therapeutics, Inc. (VERA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results — Barrons.com
By Mackenzie TatananniVera Therapeutics tightened its race against market rivals on Tuesday as the biotechnology company released fresh data for its injectable kidney drug, Trutakna.Late-stage trial results show promise
EQUITY | Sep 15, 2026, 04:04 PM UTC
L
VERA Stock Jumps 16% Premarket — Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4
Vera Therapeutics Inc. (VERA) shares surged in Tuesday’s premarket trading after the company reported positive final Phase 3 results for Trutakna in adults with IgA nephropathy.Trutakna is Vera’s treatment for IgA nephro
REGULATION | Sep 15, 2026, 01:08 PM UTC
L
Vera Therapeutics Shares Gain on Positive Late-Stage Trial Results
By Connor HartShares of Vera Therapeutics climbed after the company said Trutakna, a treatment which helps mitigate the progression of certain kidney diseases, met all prespecified endpoints in a late-stage trial.The sto
EQUITY | Sep 15, 2026, 11:19 AM UTC
L
Vera set for full FDA approval of Trutakna after late-stage trial win
Vera Therapeutics NASDAQ:VERA added more than 10% in premarket trading on Tuesday after announcing plans to seek full FDA approval for its lead asset Trutakna following a late-stage trial win in primary IgA nephropathy,
REGULATION | Sep 15, 2026, 11:18 AM UTC
L
Vera: TRUTAKNA stabilizes eGFR, cuts kidney-progression risk 76% in ORIGIN 3 final analysis
Vera announced TRUTAKNA met all prespecified endpoints in ORIGIN 3, stabilizing eGFR and reducing kidney—disease progression risk by 76%.Key Highlights:Original SEC Filing: Vera Therapeutics, Inc. [ VERA ] - 8-K - Sep. 1
REGULATION | Sep 15, 2026, 10:53 AM UTC
L
VERA - Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
VERA - Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
NEWS | Sep 15, 2026, 10:30 AM UTC
L
VERA: Trutakna's launch marks a major advance in IgA nephropathy care, with strong early uptake
Trutakna launched following July approval, targeting IgA nephropathy with strong efficacy and safety data, and a broad commercial strategy. Early launch metrics are positive, with robust payer support and a focus on expa
EQUITY | Sep 10, 2026, 01:26 PM UTC
L
VERA: TRUTAKNA launches with strong efficacy, broad access, and robust early commercial traction
TRUTAKNA's commercial launch follows strong clinical data showing kidney function preservation and proteinuria reduction in IgA nephropathy. The product's premium pricing, broad label, and convenient dosing support a lar
EQUITY | Sep 10, 2026, 12:51 PM UTC
L
Vera Therapeutics kept at Overweight; JP Morgan lifts PT
JP Morgan maintained Vera Therapeutics at Overweight and raised its price target to $83.00 per share from $76.00, according to TradingView News via Benzinga ratings actions.
EQUITY | Sep 08, 2026, 03:57 PM UTC
L
Vera Therapeutics announces Nasdaq Rule 5635(c)(4) inducement grants
Vera Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:05 PM UTC
L
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics says it will participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 11:30 AM UTC
H
Kura Sushi Posts Weak Q3 Sales, Joins FuelCell Energy And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Wednesday. Shares of Kura Sushi USA, Inc. (NASDAQ: KRUS ) fell sharply in pre-market trading after the company reported wor
EARNINGS | Jul 08, 2026, 12:04 PM UTC
L
Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
H.C. Wainwright raised the firm's price target on Vera Therapeutics to $125 from $110 and keeps a Buy rating on the shares after the FDA granted accelerated approval to Trutakna with "a broad and clean label" to reduce p
REGULATION | Jul 08, 2026, 10:28 AM UTC
L
Vera Therapeutics price target raised to $70 from $65 at BofA
BofA raised the firm's price target on Vera Therapeutics to $70 from $65 and keeps a Buy rating on the shares following Trutakna's conditional FDA approval for the treatment of immunoglobulin A nephropathy. Trutakna's Ig
REGULATION | Jul 07, 2026, 06:09 PM UTC
L
Vera's Trutakna approved by FDA for adults with primary IgA nephropathy
The U.S. Food and Drug Administration has approved Trutakna to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. Trutakna is injected subcutaneously once weekly. The
EQUITY | Jul 07, 2026, 04:29 PM UTC